Buy Tirzepatide 45mg: High-Purity Dual GIP/GLP-1 Agonist for Advanced Research

Tirzepatide (45mg) is a potent dual GIP and GLP-1 receptor agonist extensively investigated in metabolic and obesity research. Studies emphasize its capacity to enhance insulin sensitivity, regulate appetite, drive substantial weight loss, and provide potential cardiovascular benefits. This research-grade peptide, supplied in a 45mg vial with 99% purity, supports in-depth explorations of incretin pathways, dose-response dynamics, and long-term metabolic effects.

Molecular Formula: C225H348N48O68 Molecular Weight: 4813.527 g/mol Purity: 99%

Important Notice: These peptides are strictly intended for research and laboratory use only. Not for human consumption, diagnostic, or therapeutic purposes. Please review and agree to our Terms and Conditions before ordering.

What is Tirzepatide?

Tirzepatide is a synthetic polypeptide engineered as a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This synergistic action amplifies effects on glucose homeostasis and energy balance beyond single-agonist compounds.

Pivotal research programs (e.g., SURPASS for type 2 diabetes models and SURMOUNT for obesity/overweight) have shown tirzepatide’s dose-dependent superiority in glycemic control and body weight reduction. While approved clinical protocols typically reach a maximum of 15mg weekly via titration, higher-concentration research formats like 45mg enable reconstitution flexibility for investigating extended dosing, maximal exposure simulations, stability testing, bulk peptide applications, or comparative studies in metabolic models.

Mechanism of Action

Tirzepatide activates key incretin pathways to:

• Stimulate glucose-dependent insulin release from pancreatic beta cells
• Suppress glucagon secretion
• Slow gastric emptying for prolonged satiety
• Modulate central appetite centers to reduce caloric intake

This dual GIP/GLP-1 engagement yields enhanced insulin sensitivity, reduced fasting/postprandial glucose, and pronounced fat mass loss in experimental settings.

Key Research Findings and Benefits

Tirzepatide demonstrates exceptional performance in metabolic investigations.

Glycemic Control in Type 2 Diabetes Models

Trials report HbA1c reductions up to -2.3% to -2.46% at higher doses, with many models achieving normoglycemic levels. The 45mg vial facilitates precise high-concentration preparations for advanced mechanism or tolerance studies.

Weight Loss and Obesity Research

In obesity-focused trials, top doses achieved average reductions of up to ~21% body weight over 72 weeks, with significant portions reaching ≥20% loss. Research also explores tirzepatide’s potential to prevent diabetes onset (risk reductions up to 94% in pre-diabetic models) and target visceral fat.

Cardiovascular and Broader Metabolic Effects

Investigations reveal improv

Tirzepatide 45mg

ements in blood pressure, lipid profiles (decreased triglycerides/LDL, increased HDL), and possible risk mitigation for cardiometabolic events.

Research Applications

The 45mg strength is particularly suited for:

• Type 2 diabetes pathway and therapy adjunct studies
• Obesity and overweight experimental models
• High-dose reconstitution, pharmacokinetics, and stability assessments
• Incretin biology, metabolic syndrome, and dose-escalation simulations

Common reconstitution in labs: Dissolve in bacteriostatic water (e.g., 4.5 mL for ~10 mg/mL) to support flexible dosing protocols from low starting levels upward.

Why Select 99% Pure Tirzepatide 45mg?

Our tirzepatide 45mg delivers ≥99% purity for consistent, high-fidelity results in peptide-receptor binding, insulin signaling, and chronic metabolic outcome experiments. Vacuum-sealed and third-party verified to reduce impurities and variability.

In summary, Tirzepatide 45mg serves as a high-capacity, versatile reagent for pioneering research into dual-incretin therapies, weight loss mechanisms, diabetes management, and metabolic optimization. Advance your studies with this premium research tool.

Latest Testing: Link to Report